A 12-month extension to: a randomized, double-blind, double-dummy, parallel-group, multicenter study to evaluate and compare the effects of once weekly alendronate and risedronate on bone mineral density in postmenopausal women with osteporosis.
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Alendronic acid; Risedronic acid
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 04 Oct 2005 New trial record.